Drug intelligence / Profile preview

ispaghula husk + senna

Development stage: Unknown
Lead developer: Incepta Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Ispaghula husk + senna is a combination laxative product containing two plant-derived active ingredients: ispaghula husk (psyllium) and senna extract. Ispaghula husk acts as a bulk-forming laxative by absorbing water in the intestinal lumen to form a gel, which increases stool mass and stimulates natural contraction. Senna extract contains sennosides that are metabolized by colonic bacteria into active rheinanthrones, which directly stimulate the myenteric plexus and intestinal smooth muscle to increase peristalsis. This dual-action mechanism is indicated for the treatment of acute and chronic constipation and has been studied for efficacy in patients with advanced chronic kidney disease.

Brand names: ManevacGastroLaxAgiolax
Other names: psyllium + sennaispaghula + senna

Beyond the preview

Go deeper on ispaghula husk + senna.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ispaghula husk + senna.

Explore the full profile